91̽»¨

While it may sound like something that only happens in a lab, you will actually find applications of synthetic biology in your supermarket, as well as your clothing and medicine cabinet. At its core, synthetic biology is the application of engineering to biology. This could mean designing DNA to code microbes and enzymes to act in desired ways, much like code to run a program.

For a country that heavily invests in a bio-economy, it is safe to say synthetic biology is not a niche interest. The UK has built research centers, biofoundries and a rapidly growing market of biologically based entrepreneurial activity. Additionally, the funding for this activity has increased significantly. 

What is Synthetic Biology?

Synthetic biology is the manipulation of cells and organisms as if they were tiny factories. By inserting specific genetic codes and combining different genetic pieces, scientists are able to get organisms to produce proteins, chemicals or materials. Unlike other forms of genetic engineering, synthetic biology is more intentional and scalable. Rather than the trial and error of genetic engineering it is more about planning and designing than building and testing.

From Laboratory To Grocery

Some of the most visible everyday applications are on your plate. Precision fermentation, using engineered microbes to brew specific proteins or fats rather than growing an entire animal or plant, is being used to make animal-free dairy proteins, egg whites and even fats used in cooking oils and chocolate. The UK-based firm Clean Food Group is a prime example, focusing on developing animal-free fats and oils, aiming to replace palm oil. The firm has received both private investments and an Innovate UK grant. CHAIN Biotech out of Nottingham, is working in collaboration with the Synthetic Biology Research Centre to create a range of live biotherapeutic products covering gut health. This is an example of the growing collaboration between ‘bio tech’ and ‘med tech’ across the country. 

Materials And Manufacturing You Don’t Even Notice

Synthetic biology is quietly replacing fossil-fuel-derived ingredients in everyday objects. Government-backed research programmes have spent years funding UK university centres, including Edinburgh, Manchester and Warwick, to explore how engineered bacteria can produce chemicals for things as mundane as toothbrushes, packaging and textiles.

London-based Touchlight has built a DNA production platform that’s reshaping how genetic material is manufactured at scale, while Nottingham’s NunaBio has raised funding to expand cell-free synthetic DNA manufacturing capacity in the UK, addressing a bottleneck that’s slowed the wider industry.

Healthcare: Living Medicines and Smarter Diagnostics

The evolution of healthcare has been remarkable with the innovation of living medicines and personalised diagnostics. Engineered living medicines are evolving as bacteria that detect specific stimuli and/or signals in the body and respond by producing specific medicines in the body. CAR-T cell therapies, where a patient’s immune cells are reprogrammed to target cancer, are also becoming more precisely controllable thanks to synthetic biology techniques.

UK biotech funding routes reflect how central this has become to the country’s health innovation strategy. Innovate UK’s Biomedical Catalyst offers up to £2 million for biotech R&D, covering up to 70% of costs for smaller companies, while government-backed investors like British Patient Capital and UKI2S continue to back early-stage synthetic biology ventures alongside private specialists such as Syncona.

Why Investors Are Paying Attention

Investors are recognising the potential of synthetic biology in the UK. Biotech and health tech have captured a large portion of venture funding in the UK and for good reason. UK based biotech startups have raised large funding rounds to further develop their research on RNA and DNA. Other startups have raised funding to research and develop new microbiome therapeutics.

Support isn’t limited to venture capital either. SynbiCITE, the national hub established to accelerate synthetic biology commercialisation, has helped dozens of UK companies reach a combined market capitalisation in the hundreds of millions of pounds, with additional funding commitments from VC-backed vehicles like SynBioVen extending that support further.

Why This Matters For UK Startups And Consumers Alike

From a startup founder’s perspective, the field of synthetic biology is rapidly advancing and is expected to play a significant role in developing alternatives to currently unsustainable forms of commerce and industry. Fields related to synthetic biology are expected to touch the lives of consumers in the near term.

While some challenges in the field remain, chief among them the ability to win the trust of the consumer and the health authority, the future of the field is promising. Synthetic biology will only continue to expand and deepen its presence in the world economy and the everyday life of people.